Michel Darnaud
Chief Executive Officer bei STENTYS
Profil
Michel Paul Darnaud currently works at Stentys SA, as Chairman & Chief Executive Officer from 2019, Aditlys Medical AG, as Director, Physidia SAS, as Director, and MicroPort Cardiac Rhythm Management International Ltd., as Independent Non-Executive Director.
Mr. Darnaud also formerly worked at European Medical Device Industry Association, as Chairman from 2004 to 2005, OnSource Corp., as Director in 2005, Ceragenix Pharmaceuticals, Inc., as Director from 2005 to 2010, Xeltis AG, as Director in 2015, CorWave SA, as Independent Director, Baxter International, Inc., as President-European Cardiovascular Business, Boston Scientific Corp., as President-European Division in 2005, Diagnostica Stago, Inc., as General Manager in 1991, and LivaNova Plc, as President-Cardiac Surgery from 2015 to 2017.
Mr. Darnaud received his undergraduate degree in 1973 from École des Hautes Études Commerciales de Paris.
Aktive Positionen von Michel Darnaud
| Unternehmen | Position | Beginn |
|---|---|---|
| STENTYS | Chief Executive Officer | 10.05.2019 |
Physidia SAS
 Physidia SAS Miscellaneous Commercial ServicesCommercial Services Physidia SAS is a research and French development company that specializes in physical and natural sciences. The company was founded in 2010 and is based in Saint-Barthelemy d'Anjou, France. | Director/Board Member | - |
| Aditlys Medical AG | Director/Board Member | - |
MicroPort Cardiac Rhythm Management International Ltd.
 MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Director/Board Member | - |
Ehemalige bekannte Positionen von Michel Darnaud
| Unternehmen | Position | Ende |
|---|---|---|
| LIVANOVA PLC | Corporate Officer/Principal | 29.03.2017 |
Ceragenix Pharmaceuticals, Inc.
 Ceragenix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ceragenix Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on infectious disease and dermatology. It offers two base technologies: Ceragenins and Barrier Repair. The Ceragenins is used for the treatment of infectious disease and Barrier Repair Technology is used for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders and others. The company was founded in 2002 and is headquartered in Denver, CO. | Director/Board Member | 23.07.2010 |
| OnSource Corp. | Director/Board Member | 27.06.2005 |
| BOSTON SCIENTIFIC CORPORATION | Corporate Officer/Principal | 01.06.2005 |
| European Medical Device Industry Association | Chairman | 01.01.2005 |
Ausbildung von Michel Darnaud
| École des Hautes Études Commerciales de Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| BOSTON SCIENTIFIC CORPORATION | Distribution Services |
| LIVANOVA PLC | Health Technology |
| Private Unternehmen | 10 |
|---|---|
| OnSource Corp. | Consumer Services |
Ceragenix Pharmaceuticals, Inc.
Ceragenix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ceragenix Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on infectious disease and dermatology. It offers two base technologies: Ceragenins and Barrier Repair. The Ceragenins is used for the treatment of infectious disease and Barrier Repair Technology is used for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders and others. The company was founded in 2002 and is headquartered in Denver, CO. | Health Technology |
Diagnostica Stago, Inc.
 Diagnostica Stago, Inc. Medical SpecialtiesHealth Technology Diagnostica Stago, Inc. provides medical, dental and hospital equipment. It serves the clinical and research hemostasis laboratory communities. The firms products are viscosity based detection system, reagents, instruments and accessories. The company is located in Parsippany, NJ. | Health Technology |
Stentys SA
 Stentys SA Medical SpecialtiesHealth Technology Stentys SA engages in the design, development, and marketing of self-expanding stents used in treating cardiovascular diseases. It provides solutions for the treatment of acute myocardial infarction and other complex coronary diseases. Its products include Xposition S, Devoir, AmazoniaSir, stemiCath, Yangtzenano and YangtzeNC. The company was founded by Gonzague Issenmann and Jacques Seguin on July 6, 2006 and is headquartered in Neuilly-sur-Seine, France. | Health Technology |
| European Medical Device Industry Association | |
Xeltis AG
 Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Health Technology |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France. | Health Technology |
| Aditlys Medical AG | |
Physidia SAS
Physidia SAS Miscellaneous Commercial ServicesCommercial Services Physidia SAS is a research and French development company that specializes in physical and natural sciences. The company was founded in 2010 and is based in Saint-Barthelemy d'Anjou, France. | Commercial Services |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Finance |
